BioHorizon Health Technology Surveillance Update: February 8, 2010
February 8, 2010 by tim · Leave a Comment
The BioHorizon Health Technology Surveillance Update gives readers a concise, high level overview of the most important emerging health technology developments on a ongoing basis including key FDA approvals, substantive clinical trial results and upcoming events of importance. First of all, on behalf of the entire BioHorizon staff, let me welcome you to the BioHorizon Health [...]
Wyeth’s Enbrel for treatment of Psoriasis
July 30, 2004 by admin · Leave a Comment
On July 30, 2004 Wyeth reported that a European Commission panel had recommended that regulators approve Enbrel as a treatment for psoriasis after other treatments were found inadequate or inappropriate. The Committee for Medicinal Products for Human Use will report its findings to the European Commission for endorsement before Enbrel can receive marketing approval. Wyeth [...]
Amgen’s Enbrel for Psoriasis
April 30, 2004 by admin · Leave a Comment
On April 30, 2004 Amgen Inc. announced that its biological therapy Enbrel® (etanercept) had received approval from the FDA. The drug is approved for the treatment of psoriasis in adult patients who are candidates for systemic therapy and who suffer from chronic moderate-to-severe plaque psoriasis. This most recent approval adds to Enbrel’s previously approved indications [...]
Humira (adalimumab) for rheumatoid arthritis
April 9, 2004 by admin · Leave a Comment
In December of 2002, Abbott Laboratories received FDA approval for Humira®, its human monoclonal antibody for the treatment of adults with moderate to severe rheumatoid arthritis. At that time, Biohorizon placed Humira in its High Impact Technology category and recommended preliminary assessment activites. In an April 2004 company news release, Abbott announced that worldwide sales [...]